Table 1. Nucleoside analogues selected for this study.
| Nucleoside analoguea | Generic name | Therapeutic useb | Base | References |
|---|---|---|---|---|
| Antiherpesvirus | ||||
| ACV | Aciclovir | HSV-1, HSV-2 and VSV treatment, EBV and CMV prevention | G | (37, 38) |
| GCV | Ganciclovir | Treatment of CMV infections | G | (39) |
| Anticancer | ||||
| CFB | Clofarabine | Treatment of ALL in children after failure. | Ac | (40, 41) |
| NRTIs | ||||
| D4T | Stavudine | HIV/AIDS therapy | T | (42, 43) |
| ddI | Didanosine | HIV/AIDS therapy | Hd | (44, 48, 49) |
| ddAe | Dideoxy A | A | ||
| ABC | Abacavir | HIV/AIDS therapy | Φf | (45, 50, 51) |
| CBVg | Carbovir | G | ||
aACV: Acycloguanosine; GCV: 2′-Nor-2′-deoxyguanosine; CFB: 2-chloro-9-(2′-Deoxy-2′-fluoro-beta-D-arabinofuranosyl)adenine; d4T: 2′,3′-didehydro-2′,3′-dideoxythymidine; ddI: 2′,3′-dideoxyinosine; ddA: 2,3′-Dideoxyadenosine; ABC: (1S, 4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]cyclopent-2-en-1-yl}methanol; CBV (1S, 4R)-4-[2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl]cyclopent-2-en-1-yl]methanol.
bHSV-1: Herpes simplex virus type I; HSV-2: Herpes simplex virus type II; VSV: Varicella zoster virus; EBV: Epstein-Barr virus; CMV: Cytomegalovirus; ALL: Acute Lymphoblastic Leukaemia.
c2-Chloro-adenine.
dHypoxanthine.
eCellular converted form of ddI.
fNon-natural (2-amino-6-(cyclopropylamino)purine).
gCellular converted active form of ABC.